ライフサイエンスコーパス: RAEB

1 ractory anaemia with excess blasts (RAEB)-1, RAEB-2, RAEB-t, or chronic myelomonocytic leukaemia base

2 SF mutations were found in 10 RAEB, 12 AML cases with low marrow blast cell count, and

3 JMML, 31% +/- 26%; RA and RAEB, 29% +/- 16%; RAEB-T, 30% +/- 18%; antecedent MDS, 50% +/- 25%; and de

4 marily by marrow blast percentage (5% to 19% RAEB, 20% to 29% RAEB-t, and > or = 30% AML).

5 anaemia with excess blasts (RAEB)-1, RAEB-2, RAEB-t, or chronic myelomonocytic leukaemia based on loc

6 blast percentage (5% to 19% RAEB, 20% to 29% RAEB-t, and > or = 30% AML).

7 SRSF2(mut) patients clustered in RAEB-1 and RAEB-2 subtypes and exhibited pronounced thrombocytopeni

8 ry anemia with excess blasts (RAEB) (4), and RAEB-in transformation (RAEB-t) (2).

9 in RAEB than in AML or RAEB-t, with AML and RAEB-t being identical.

10 (CFU)-leukemia formation in 9 of 15 CMML and RAEB-t patient specimens, whereas VEGF stimulated leukem

11 s were as follows: JMML, 31% +/- 26%; RA and RAEB, 29% +/- 16%; RAEB-T, 30% +/- 18%; antecedent MDS,

12 xcess blasts in transformation (RAEB-T), and RAEB-T/secondary MDS.

13 lasts from NECs, 72 patients were recoded as RAEB-2 and showed an inferior overall survival than did

14 s (5), refractory anemia with excess blasts (RAEB) (4), and RAEB-in transformation (RAEB-t) (2).

15 refractory anemia (RA) or RA-excess blasts (RAEB) exhibited high induction failure rates and overall

16 of 47 refractory anemia with excess blasts (RAEB) patients, 29 AML cases with low marrow blast cell

17 , while patients with RA with excess blasts (RAEB) show significantly increased levels of activity (P

18 h-risk refractory anemia with excess blasts (RAEB) stages of MDS, the GMP population is increased in

19 y anemia (RA), 19 had RA with excess blasts (RAEB), 16 had RAEB in transformation or acute myelogenou

20 oblasts (RARS), 5 had RA with excess blasts (RAEB), and 1 had chronic myelomonocytic leukemia (CMMoL)

21 is of refractory anaemia with excess blasts (RAEB)-1, RAEB-2, RAEB-t, or chronic myelomonocytic leuka

22 tions, refractory anemia with excess blasts (RAEB)-2 diagnosis is not possible in MDS-E, as patients

23 s with refractory anemia with excess blasts (RAEB).

24 t), or refractory anemia with excess blasts (RAEB).

25 MDS-refractory anemia with excess of blasts (RAEB) and MDS/AML.

26 or refractory anemia with excess of blasts (RAEB) entering CR-MDA from 1995 to 2000 had no PBBs at t

27 A] and refractory anemia with excess blasts [RAEB-1]) with ATG (40 mg/kg/d for 4 days) and prednisone

28 (MDS) (refractory anemia with excess blasts [RAEB] or RAEB-t, 62 patients) to receive fludarabine + a

29 ation (refractory anemia with excess blasts [RAEB]/AML).

30 se of this analysis was to see if diagnosis (RAEB, RAEB-t, or AML) affected outcome.

31 % for secondary AML, 40% for RAEB-T, 26% for RAEB, and 0% for RA or RARS (P =.0009).

32 disease morphology (66% for RAEB-T v 38% for RAEB and CMML, P = .05).

33 f relapse was 40% for secondary AML, 40% for RAEB-T, 26% for RAEB, and 0% for RA or RARS (P =.0009).

34 P = .04) and on disease morphology (66% for RAEB-T v 38% for RAEB and CMML, P = .05).

35 19 had RA with excess blasts (RAEB), 16 had RAEB in transformation or acute myelogenous leukemia (RA

36 SRSF2(mut) patients clustered in RAEB-1 and RAEB-2 subtypes and exhibited pronounced thro

37 as well as overall survival, were poorer in RAEB than in AML or RAEB-t, with AML and RAEB-t being id

38 oduced a 62% complete remission (CR) rate in RAEB, essentially identical to the rates in RAEB-t and A

39 RAEB, essentially identical to the rates in RAEB-t and AML, but event-free survival (EFS) from CR an

40 ransformation or acute myelogenous leukemia (RAEB-T/AML), and 2 had chronic myelomonocytic leukemia (

41 The poor prognosis of many RAEB or RAEB-t patients, if untreated, led us to give th

42 planted mice, followed by progression to MDS-RAEB or MDS/AML.

43 Our study provides evidence that SF-mutant RAEB and SF-mutant AML are clinically, cytologically, an

44 We conclude that SF-mutant RAEB/AML constitutes a related disorder overriding the a

45 tion between AML and MDS, and that SF-mutant RAEB/AML is composed of 2 molecularly and clinically dis

46 tient clusters highly enriched for SF-mutant RAEB/AML.

47 seen in 79% of early MDS samples and 90% of RAEB/AML samples, and were not as widely distributed ove

48 togenetics, age, etc, but not a diagnosis of RAEB or RAEB-t per se.

49 As previously found, a diagnosis of RAEB or RAEB-t rather than AML was insignificant.

50 ther patient characteristics, a diagnosis of RAEB rather than AML or RAEB-t had no effect on EFS from

51 S from start of Rx than patients with AML or RAEB (P = .08; relative risk, 0.80; 95% confidence inter

52 tics, a diagnosis of RAEB rather than AML or RAEB-t had no effect on EFS from start of Rx, EFS from C

53 survival, were poorer in RAEB than in AML or RAEB-t, with AML and RAEB-t being identical.

54 ]), numbers increased in patients with RA or RAEB (160.2% +/- 90.5% of untreated group).

55 Patients with RA or RAEB respond poorly to AML induction therapy.

56 The poor prognosis of many RAEB or RAEB-t patients, if untreated, led us to give them AML R

57 cs, age, etc, but not a diagnosis of RAEB or RAEB-t per se.

58 As previously found, a diagnosis of RAEB or RAEB-t rather than AML was insignificant.

59 However, patients with RAEB or RAEB-t were more likely to have poor prognostic characte

60 dministering AML Rx to patients with RAEB or RAEB-t who have poor prognosis without treatment is iden

61 fractory anemia with excess blasts [RAEB] or RAEB-t, 62 patients) to receive fludarabine + ara-C + id

62 excess blasts in transformation (RAEB-t), or RAEB.

63 this analysis was to see if diagnosis (RAEB, RAEB-t, or AML) affected outcome.

64 intensity of MRI signals correlated with the RAEB subtype, particularly with transformation into acut

65 ition, transplantation before progression to RAEB-T, if possible, may reduce the risk of relapse.

66 asts (RAEB) (4), and RAEB-in transformation (RAEB-t) (2).

67 es for patients with RAEB in transformation (RAEB-T) (69%) or antecedent MDS (81%) were similar to de

68 anemia with excess blasts in transformation (RAEB-T) had apoptosis levels in lymphocytes similar to t

69 anemia with excess blasts in transformation (RAEB-t), and especially patients with RAEB, receive chem

70 anemia with excess blasts in transformation (RAEB-T), and RAEB-T/secondary MDS.

71 anemia with excess blasts in transformation (RAEB-t), or RAEB.

72 anemia with excess blasts in transformation (RAEB-t), or refractory anemia with excess blasts (RAEB).

73 anemia with excess blasts in transformation [RAEB-T] and tAML [MDS transformed into AML]), colony num

74 yelocytic leukemia [APL] excluded), 106 with RAEB-t, and 52 with RAEB.

75 APL] excluded), 106 with RAEB-t, and 52 with RAEB.

76 Remission rates for patients with RAEB in transformation (RAEB-T) (69%) or antecedent MDS

77 However, patients with RAEB or RAEB-t were more likely to have poor prognostic

78 ety of administering AML Rx to patients with RAEB or RAEB-t who have poor prognosis without treatment

79 Among 19 patients with RAEB, 3 had relapse (CI at 3 years, 16%), and 8 are surv

80 ation (RAEB-t), and especially patients with RAEB, receive chemotherapy regimens (AML Rx) administere

81 rior overall survival than did patients with RAEB-1 without erythroid hyperplasia.

82 analyses suggested a trend for patients with RAEB-t to have better EFS from start of Rx than patients

83 Among 18 patients with RAEB-T/AML or CMML, 6 had relapse (CI at 3 years, 28%),